Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and NanoString Tech (NSTG)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exact Sciences (EXASResearch Report) and NanoString Tech (NSTGResearch Report) with bullish sentiments.

NanoString Tech (NSTG)

Robert W. Baird analyst Catherine Ramsey Schulte reiterated a Buy rating on NanoString Tech on January 9 and set a price target of $60.00. The company’s shares closed last Tuesday at $37.37, close to its 52-week low of $35.25.

According to TipRanks.com, Schulte is a 5-star analyst with an average return of 26.0% and a 66.2% success rate. Schulte covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Twist Bioscience, and Exact Sciences.

Currently, the analyst consensus on NanoString Tech is a Strong Buy with an average price target of $68.50, which is an 84.8% upside from current levels. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $85.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on EXAS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed